Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07819656 | Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma | recruiting | — | 1,782 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02734537 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | recruiting | Phase 2 | 189 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 |
| clinicaltrials |
| NCT04090567 | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | recruiting | Phase 3 | 580 | M.D. Anderson Cancer CenterOTHER | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04644952 | The Rise in Robotic Atypical Segmentectomies | recruiting | — | 600 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04723095 | Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix(NeCTuR) | recruiting | — | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04858009 | Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04977453 | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 317 | GI Innovation, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05752149 | Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial(STELLAR) | recruiting | Phase 2 | 27 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06064097 | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 5 | Sep 14, 2026 | clinicaltrials |
| NCT06246968 | A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer | recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06303505 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC(NAPISTAR1-01) | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT06503614 | A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer(ENHANCE) | recruiting | Phase 2 | 60 | John SfakianosOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06557733 | An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis | recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06732388 | Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus | recruiting | Phase 2 | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06789198 | Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA(FusionVAC22_02) | recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07020806 | [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC) | recruiting | Phase 1 | 30 | University of California, DavisOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07113691 | Iadademstat + SBRT With Atezo in ES-SCLC(TIARA) | recruiting | Phase 1 | 15 | Yale UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)(DLLEVATE) | recruiting | Phase 3 | 480 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT07325136 | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 240 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 14, 2026 | clinicaltrials |
| NCT07391956 | Tier Palliative Care For Patients With Advanced Heart Failure or Cancer(TIER-PC) | recruiting | N/A | 400 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07513389 | Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) | recruiting | Phase 2 | 36 | Medical University of South CarolinaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07516366 | Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial | recruiting | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07615374 | Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer | recruiting | N/A | 36 | Jilin UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07772869 | Uterine Lavage to Detect Ovarian Cancer Risk | recruiting | N/A | 75 | University of WashingtonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818135 | Comparison of Biportal Versus Multiportal Robotic Approaches for Pulmonary Resection in NSCLC(EC-UMUR) | recruiting | N/A | 80 | Carlos DénizOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04410796 | Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | recruiting | Phase 2 | 571 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05306041 | Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer(GeparPiPPa) | recruiting | Phase 2 | 170 | GBG Forschungs GmbHOTHER | 6 | Sep 11, 2026 | clinicaltrials |
| NCT05365581 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | recruiting | Phase 1 | 398 | Astellas Pharma Global Development, Inc.INDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT05630794 | Testing for Safety and Colorectal Cancer Preventive Effects of ONC201 | recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05710679 | Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer(NeckTAR) | recruiting | N/A | 63 | Centre Jean PerrinOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05753748 | Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia(SURVENT) | recruiting | N/A | 680 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05845450 | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | recruiting | Phase 2 | 197 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05850130 | Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients(ACUPOX) | recruiting | N/A | 182 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05935384 | SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation | recruiting | — | 470 | Guardant Health, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06309485 | Phase 2 Study of WGI-0301 for Advanced HCC | recruiting | Phase 2 | 60 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06487403 | HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers(HN-Bio 02) | recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06651580 | Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | recruiting | — | 1,600 | M.D. Anderson Cancer CenterOTHER | 4 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | recruiting | Phase 3 | 840 | AstraZenecaINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 15, 2026source: clinicaltrials